Table 6 Clinical benefit by tumor subtypes and treatment line
Characteristics | Clinical benefit N (%) | P |
|---|---|---|
Triple negative | ||
Yes | 6 (23.1) | n.s. |
Not | 30 (34.5) | |
ER/PgR status | ||
ER and/or PgR positive | 28 (33.3) | n.s. |
ER and/or PgR negative | 12 (41.4) | |
HER2 | ||
Overexpressed/amplified | 6 (46.1) | n.s. |
Not overexpressed/amplified | 32 (34.8) | |
Dominant disease site | ||
Visceral | 34 (40) | 0.07 |
Non visceral | 6 (21.4) | |
Metastatic disease site | ||
1 | 5 (27.8) | n.s. |
≥2 | 35 (36.8) | |
Number of prior chemotherapy for advanced disease | ||
2 | 12 (35.3) | n.s. |
≥3 | 28 (35.4) |